Please check your internet connection and try again.
# Septran (Co-trimoxazole)
## Overview
Septran is a combination antibiotic containing trimethoprim and sulfamethoxazole. It is a bacteriostatic agent that inhibits sequential steps in the folic acid synthesis pathway.
## Primary Indications
* **Urinary Tract Infections (UTIs):** Acute uncomplicated UTIs.
* **Pneumocystis jirovecii Pneumonia (PJP) Prophylaxis and Treatment:** Especially in immunocompromised patients.
* **Shigellosis.**
* **Prophylaxis against other opportunistic infections** in specific immunocompromised populations.
## Adult Dosing
* **Acute Uncomplicated UTIs:** 1 double-strength (DS) tablet (160 mg trimethoprim/800 mg sulfamethoxazole) orally every 12 hours for 3 days.
* **PJP Treatment:** 15-20 mg/kg/day (trimethoprim component) divided into 3-4 doses orally or IV, usually for 14-21 days.
* **PJP Prophylaxis:** 1 DS tablet orally once daily, or 1 DS tablet orally 3 times a week.
* **Shigellosis:** 1 DS tablet orally every 12 hours for 5 days.
*Note: Dosing for specific indications may vary based on local protocols and susceptibility patterns.*
## Pediatric Dosing
Dosing is based on the trimethoprim component, 8 mg/kg/day, divided into 2 doses, not to exceed the adult dose.
* **UTIs and Shigellosis:** 8 mg/kg/day of trimethoprim, divided into 2 doses every 12 hours. For example, for a 20 kg child, the dose would be approximately 1 DS tablet per day divided into two doses.
* **PJP Treatment:** 15-20 mg/kg/day (trimethoprim component) divided into 3-4 doses orally or IV.
* **PJP Prophylaxis:** 150 mg/m²/day (trimethoprim component) orally in 2 divided doses, 3 times per week.
*Note: Pediatric dosing requires careful calculation and is often guided by weight and body surface area. Consult specific pediatric guidelines.*
## Dose Adjustments
* **Renal Impairment:**
* CrCl > 30 mL/min: No adjustment needed.
* CrCl 15-30 mL/min: Administer 75% of the usual dose.
* CrCl < 15 mL/min: Avoid use. If unavoidable, administer 50% of the usual dose.
## Contraindications
* Known hypersensitivity to trimethoprim, sulfamethoxazole, or sulfonamides.
* History of drug-induced immune thrombocytopenia with either component.
* Marked liver or renal damage.
* Megaloblastic anemia due to folate deficiency.
* Premature infants and full-term infants during the first 2 months of life.
## Adverse Effects
* **Common:** Rash (can be severe, Stevens-Johnson syndrome), nausea, vomiting, diarrhea, pruritus.
* **Hematologic:** Thrombocytopenia, leukopenia, neutropenia, aplastic anemia, megaloblastic anemia (especially with prolonged use or in folate-deficient individuals).
* **Renal:** Crystalluria (ensure adequate hydration), interstitial nephritis.
* **Hepatic:** Elevated liver enzymes, hepatitis.
* **Electrolyte:** Hyperkalemia.
* **Other:** Photosensitivity, serum sickness-like reactions.
## Key Drug Interactions
* **Warfarin:** Increased INR. Monitor INR closely and adjust warfarin dose.
* **ACE Inhibitors/ARBs/Potassium-Sparing Diuretics:** Increased risk of hyperkalemia.
* **Methotrexate:** Increased methotrexate levels and toxicity.
* **Potassium Supplements/Potassium-Containing Salt Substitutes:** Increased risk of hyperkalemia.
* **Cyclosporine:** Increased cyclosporine levels and nephrotoxicity.
* **Digoxin:** Increased digoxin levels.
* **Oral Contraceptives:** May reduce efficacy.
* **Phenytoin:** Increased phenytoin levels.
* **Sulfonylureas:** Increased risk of hypoglycemia.
* **Uricosuric agents (e.g., probenecid):** May increase serum concentrations of co-trimoxazole.
## Monitoring
* **Renal function (BUN, creatinine).**
* **Complete blood count (CBC) with differential:** Especially with prolonged therapy, in elderly patients, or those with G6PD deficiency.
* **Electrolytes (especially potassium).**
* **Liver function tests.**
* **Signs and symptoms of hypersensitivity reactions.**
* **Hydration status** to prevent crystalluria.
## Clinical Pearls
* Co-trimoxazole is a frequently used antibiotic for UTIs and PJP.
* Ensure adequate fluid intake to prevent crystalluria.
* Patients with G6PD deficiency are at increased risk of hemolytic anemia.
* Discontinue immediately if rash occurs, as it can be a sign of severe hypersensitivity.
* Monitor potassium closely, especially in patients with renal impairment or those on other medications that can increase potassium.
* For PJP prophylaxis, adherence is crucial for efficacy.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and local institutional guidelines before making any clinical decisions. Dosing and recommendations can change.*
